AYTU Q4 2024: ADHD Scripts Climb 26% as Pediatric Recovery Signals Portfolio Rebound
Aytu Biopharma’s strategic transformation delivered a 162% adjusted EBITDA improvement, driven by ADHD portfolio gains and decisive cost control. With consumer health fully divested and pediatric volumes rebounding sharply, the company’s core specialty Rx model is now exposed for margin expansion and renewed growth. Early fiscal 2025 data points to accelerating prescription momentum across both ADHD and pediatric lines, setting a higher baseline for future profitability.
Summary
- ADHD Franchise Reset: Prescription demand has reached an all-time high, establishing a new baseline for growth.
- Pediatric Portfolio Inflection: Unit shipments up 115% early in fiscal 2025 signal a tangible turnaround after payer headwinds.
- Margin Expansion Visibility: Wind-down of legacy operations and manufacturing shift unlocks sustainable profit leverage.
Business Overview
Aytu Biopharma (AYTU) is a specialty pharmaceutical company focused on commercializing prescription therapeutics for ADHD and pediatric indications. The company’s revenue is primarily generated through its Rx segment, which includes branded ADHD products and pediatric medications. AYTU recently exited its consumer health and in-house manufacturing operations, sharpening focus on its higher-margin specialty Rx business, with ADHD products now accounting for the vast majority of prescription sales.
Performance Analysis
AYTU’s fiscal 2024 results reflect a business model in transition, with the company executing a full pivot from consumer health and legacy manufacturing to a lean, specialty Rx focus. Net revenue for the year was $81 million, with the ADHD portfolio rising 23% year-over-year and comprising 89% of Rx revenue. Pediatric revenue, however, declined sharply due to payer disruptions, dropping to $7.3 million, though early fiscal 2025 data shows a strong rebound in unit volumes.
Gross margin expansion was a standout, reaching 67% company-wide and 75% within the Rx segment, up from 62% and 71% respectively. This improvement was driven by the exit from low-margin consumer health, the shutdown of the Grand Prairie manufacturing facility, and a shift to third-party production. Operating expenses dropped substantially as restructuring and wind-down charges were absorbed, and adjusted EBITDA swung to $9.2 million from a negative $21.5 million just two years prior.
- Prescription Demand Surge: ADHD scripts hit 438,000 in fiscal 2024, up 25% since 2021, with early Q1 2025 unit sales up 26% sequentially.
- Pediatric Volume Recovery: Pediatric unit shipments are up 115% early in fiscal 2025, indicating channel and payer fixes are gaining traction.
- Debt and Liquidity Strengthening: Debt refinancing reduced interest expense and moved maturities to 2028, supporting a $20 million cash position and eliminating going concern risk.
The net result is a more focused, margin-rich business with visible tailwinds in its core prescription franchises and a structurally improved balance sheet.
Executive Commentary
"We have positively transformed the operating profile of A2. For fiscal 24, adjusted EBITDA improved 162% to $9.2 million, compared to $3.5 million in fiscal 23. And when you look back at fiscal 22, our adjusted EBITDA was a negative $21.5 million. So over a two-year span, we've achieved a more than $30 million positive swing in our operating results, quite an achievement by the entire A2 team."
Josh Disbrow, Chief Executive Officer
"Company-wide gross margins improved to 67% for full year 2024 compared to 62% in fiscal 2023. For the quarter, this improvement was once again highlighted, with Q4 gross margins coming at 66% from 60% for the quarter last year. The improvement is a reflection of the evolving mix of our business towards the RX segment, given the wind-down of the consumer health business, coupled with efficiency improvements made across our RX segments."
Mark Occhi, Chief Financial Officer
Strategic Positioning
1. Specialty Rx Focus and Margin Expansion
AYTU’s exit from consumer health and in-house manufacturing has fundamentally reset its operating model, exposing the high-margin potential of its prescription franchise. The Rx segment now dominates revenue and profit contribution, and efficiency gains from the contract manufacturing shift are locked in, with gross margins at 75% in the core business.
2. ADHD Franchise as Growth Anchor
The ADHD portfolio is now the engine of the business, with script volumes at record highs and a normalized demand environment post-industry shortage. Management’s focus is on growing share from a sub-1% market position, leveraging RxConnect to ensure patient access and predictable economics for prescribers.
3. Pediatric Portfolio Rebuild
Though battered by payer disruptions in fiscal 2024, the pediatric division is showing early signs of recovery, with unit shipments up triple digits early in fiscal 2025. Commercial initiatives, improved reimbursement, and expanded geographic coverage are expected to drive incremental revenue and EBITDA contribution as the year progresses.
4. RxConnect Platform as Commercial Lever
RxConnect, AYTU’s pharmacy network and patient access program, provides a competitive moat by guaranteeing out-of-pocket costs and simplifying prescriber workflows. The platform enables bolt-on product launches and supports scale without significant incremental cost, underpinning management’s tuck-in product strategy.
5. Financial Flexibility and Capital Allocation
Recent debt refinancing, elimination of going concern language, and a renewed shelf registration position AYTU for opportunistic growth investments or product acquisitions. The balance sheet is now structured for stability, with extended maturities and lower interest expense supporting free cash flow objectives.
Key Considerations
AYTU’s fiscal 2024 marks a structural inflection, but execution risks remain as the business pivots from turnaround to growth mode. Investors should monitor how quickly pediatric recovery translates to revenue, and whether ADHD share gains can be sustained as industry supply normalizes and payer dynamics evolve.
Key Considerations:
- ADHD Market Share Opportunity: Company targets growth from less than 1% share, with script volumes at a new high post-shortage.
- Pediatric Revenue Recovery Pace: Early unit gains must convert to sustained revenue, with payer wins and inventory restocking critical.
- Margin Durability: Gross margin improvements rely on maintaining Rx mix and efficient contract manufacturing execution.
- RxConnect Leverage: Platform enables low-cost product additions, but scale is needed for material impact.
- Capital Allocation Discipline: Management signals focus on cash flow generation before pursuing larger acquisitions.
Risks
AYTU’s growth trajectory is exposed to payer policy shifts, especially in the pediatric segment, and competitive intensity in the ADHD market remains high. The company’s ability to sustain margin gains depends on stable product mix and contract manufacturing execution. Regulatory changes, reimbursement volatility, and slow pediatric recovery could pressure revenue and profitability. Management’s discipline in product selection and capital allocation will be tested as the company seeks to scale beyond its core ADHD franchise.
Forward Outlook
For Q1 fiscal 2025, AYTU guided to:
- ADHD and pediatric script growth, with unit shipments up 26% and 115% respectively early in the quarter.
- Continued adjusted EBITDA and net revenue growth over fiscal 2024 levels.
For full-year 2025, management raised expectations:
- Revenue and adjusted EBITDA both expected to exceed fiscal 2024 results.
Management highlighted several factors that shape the outlook:
- Restored coverage and promotional focus in pediatrics are expected to drive revenue recovery.
- Ongoing leverage of RxConnect and disciplined cost structure to support margin and cash flow expansion.
Takeaways
AYTU’s transformation is now visible in the numbers, with the core specialty Rx business delivering profitability and margin expansion. The ADHD franchise provides a stable growth anchor, while early signs of pediatric recovery could add incremental upside if sustained.
- Script Growth Drives Confidence: ADHD and pediatric volumes are rebounding, supporting management’s outlook for revenue and EBITDA gains.
- Margin and Balance Sheet Reset: Structural improvements from business exits and refinancing create a platform for free cash flow generation.
- Execution on Pediatric Recovery: Investors should watch for continued traction in pediatric sales and RxConnect-driven product additions as key forward catalysts.
Conclusion
AYTU has emerged from a multi-year turnaround with a focused, high-margin specialty Rx model and accelerating script momentum in its core franchises. The company’s operational discipline and commercial platform provide visible leverage, but sustained pediatric recovery and disciplined product expansion will determine the pace and durability of future growth.
Industry Read-Through
AYTU’s results reinforce several industry themes for specialty pharma and branded generics. First, margin expansion is increasingly tied to portfolio focus and exit from legacy or low-return businesses, as seen in AYTU’s divestiture and manufacturing shift. Second, payer volatility remains a structural risk, especially in pediatric and Medicaid-driven businesses, with recovery hinging on targeted commercial execution and coverage wins. Finally, platform commercial models like RxConnect are gaining traction as levers for scale and cost-efficient product launches, a trend likely to shape competitive dynamics across the specialty pharma landscape. Companies lacking such infrastructure may face margin and access headwinds as payers and supply chains become more complex.